My Pharma Reviews

Indian pharma’s R&D intensity has been structurally stagnant for years, sitting at roughly half of global large pharma’s spend as a share of revenue and less than a third of China’s. This is not simply a function of India being a generics-focused industry, it is a capital allocation choice, made repeatedly, by boards that have other options.

Sun Pharma’s $355-416 million acquisition of Checkpoint Therapeutics shows what disciplined innovation capital allocation looks like. A single, sizeable, strategically coherent bet on a commercial-stage specialty asset, rather than either no investment at all or a scattering of small, low-conviction bets that read well in an annual report but change nothing structurally.

• Hard benchmark numbers: Alphabet’s $61 billion annual R&D spend vs. the combined R&D spend of India’s top 10 listed pharma companies

• R&D intensity comparison: global large pharma at ~23.5% of sales, China at ~17.5%, India at ~4.4-7.5%, essentially flat for years

• The Sun Pharma-Checkpoint Therapeutics deal as a worked case study in disciplined, sizeable, strategically coherent innovation capital allocation

• What boards should be asking and typically are not, connecting back to the Ternus Test introduced in Episode 2

Listen in to Episode 7 of the Bio-Health Supercycle.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The Coefficient Bio acquisition reveals the true price of computational biology talent at the frontier. Roughly $44 million per person, paid not for revenue or product but for scarce expertise that would otherwise take years to build internally. This is not anything Indian pharma payrolls can compete with, and trying to compete on that basis is a strategic error. The realistic Indian pharma AI strategy is not to out-bid Anthropic, Google, and OpenAI for individual computational biologists but to behave more like Eli Lilly did with Insilico Medicine - pay for access to an AI-native platform’s output, rather than trying to own the scarce talent that built the platform.

• The Coefficient Bio deal anatomy: 8 months old, fewer than 10 people, $400 million, all-stock, and why that price was rational for the buyer

• Where this talent actually comes from: Genentech’s 2025 layoffs as Roche pivoted toward embedded AI, releasing exactly the computational biology talent pool that Coefficient Bio’s founders came from

• The acqui-hire versus platform-partnership distinction, using Eli Lilly’s contrasting $2.75 billion Insilico Medicine deal as the comparison case

• What this means concretely for Indian pharma: the talent-acquisition path is largely foreclosed; the platform-partnership path remains genuinely open

• The regulatory vacuum around AI-generated claims in pharma promotion and prescribing support, and the specific compliance exposure this creates for any Indian company moving fast on AI-assisted commercial tools

Listen in to Episode 6 covering Wave 5 of the Bio-Health Supercycle. “My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The semaglutide patent cliff played out almost exactly as the commodity-trap thesis predicted. Prices collapsed by up to 90 percent, more than 40 companies launched over 50 brands within weeks, and margins in the injectable semaglutide category compressed toward levels that will reward only the lowest-cost, highest-volume manufacturers.

But the data 4-8 weeks later revealed something the commodity-trap framing alone would not have predicted. Eli Lilly’s tirzepatide, sold as Mounjaro, sitting completely outside the genericisation event (because its patents do not expire until roughly 2036) captured a larger share of category growth than semaglutide did. Doctors who had patients stable on Mounjaro mostly did not switch to cheaper semaglutide generics. Some actually increased prescriptions.

This is the most important data point for understanding where actual pricing power sits in the GLP-1 category, and it is a direct, real-world confirmation of the ‘commodity trap versus the real prize’ argument first raised in Episode 2.

Listen in to the next episode of the Bio-Health Supercycle Series.

“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

A CDMO opportunity is not won by capacity announcements, MOUs, or press coverage of a competitor’s regulatory trouble. It is won through multi-year client qualification cycles, sustained GMP/FDA inspection performance, and demonstrated commercial-scale output across the specific modality a client needs.

The WuXi AppTec designation created a genuine tailwind, but the timeline for that tailwind to convert into Indian order books is longer, and the qualification bar is higher, than most coverage of this opportunity acknowledges.

Listen in.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Episode 2 diagnosed the Generics Trap at the industry level and introduced the three-cluster stratification framework in general terms. Episode 3 applies that framework with full company-level specificity to the ten biologics subsidiaries of listed Indian pharma majors. This is the most data-dense episode in the series, closer to an equity research note delivered in audio form than a macro narrative.

The deliverable for the listener is a working mental map. Ten names, three clusters, and a five-signal diagnostic they can apply themselves to any biologics subsidiary not covered here.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Episode 1 established the macro framework - six biological platform waves, the tech supercycle parallel, and where wealth concentrates in platform transitions. Episode 2 descends one level from the global arc to the Indian pharma story specifically. It answers the question that Episode 1 left hanging, if biology is the next platform, what is Indian pharma’s position on that platform and is it strong enough?

This is the diagnostic episode. It earns the right to make prescriptions in Episodes 7 through 10 by doing the structural analysis first.

For listeners’ reference here is the bio-health supercycle as i visualise it.

“My Pharma Reviews - The Podcast” is now available for you to listen on all your favourite podcasting apps - Spotify, Apple, and Youtube

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

The companies that will create SpaceX-scale wealth in bio-health will not discover the next blockbuster drug. They are the ones that will reduce the cost of discovering, manufacturing, or delivering any drug by an order of magnitude, making the entire platform cheaper, faster, and more accessible, exactly as AWS made software cheaper, TSMC made chips cheaper, and SpaceX made orbit cheaper. This is the beginning of a new series of episodes exploring where the next wealth creators will emerge from in pharma.

Listen in!

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

In the past few episodes, now that we have stratified Indian companies on R&D focus (global innovation, India-specific, and pure play generics), and CDMO players especially after the DOD 1260H list update featuring WuXi Apptech, let us think of the front end market.

On one hand we see a handful of Indian pharma majors investing in global research, and likely to embed AI into discovery, manufacturing and distribution processes. Global innovators are using AI and other tech to ease out the costs of discovery and in the future are likely to compete with Indian majors for this vast market, of course with portfolios that are vastly differentiated and difficult to copy (biologics, CGT etc).

On the other hand, we have 3 Indias in one country - India 1 (10% of the super rich) which is 100-140 miillion people, India 2 - 23% of the middle which is 300m poeple and India 3 which is ~67% of the rest (approx 1B people). These three India’s need different products, prices, promotion and places to access medicine and healthcare.

This episode deals with how pharma (global + local companies) will pan out in the next 5-10 years to cater to the three Indias while keeping their aspirations, investments across the value chain and product-market fit for the three Indias? How will companies segment these markets and what is their likely GTM strategy?

Listen in!

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

Yesterday, June 8, 2026, the US Department of Defense published its updated Section 1260H list. WuXi AppTec is on it.

WuXi AppTec is in the supply chain of roughly one in four drugs used in the United States. The Biosecure Act signed into law in December 2025 restricts US government procurement from companies on exactly this list.

The catalyst that Indian CDMO analysts have been modelling as a future scenario just became a present reality.

What it means for Indian CDMOs:

Divi’s: Confirmed GLP-1 commercial contracts. Highest-ever quarterly revenue in Q4 FY26. The China+1 tailwind just went from probable to triggered. The business is excellent. It was already at 62x FY26 earnings before this news.

Syngene: BMS partnership extended to 2035. New biologics facility operational. ADC lab launched. FY26 profit down 20% — one client, one product (Zoetis, a dog pain drug). Idiosyncratic. The WuXi designation means its research services pipeline just got more interesting, immediately.

Piramal: US and UK facilities are literally on the ground in Western markets, positioned to receive physical contract migration. $90M committed to ADC and sterile injectable scale-up. Zero OAI across 38 regulatory inspections in FY26. This is the most direct beneficiary.

What it does NOT mean

The designation is for WuXi AppTec. WuXi Biologics the separate listed subsidiary is not on the June 8 list as a standalone entity. The biologics manufacturing migration story is driven by a different set of concerns and has not yet received a formal designation.

And switching a commercial drug’s manufacturing partner still takes twelve to thirty-six months per molecule under FDA change regulations. The order books accelerate from today. The revenues follow the order books by that same lag.

RFPs spike. Contracts take months. Revenue takes years. Be precise about where in that pipeline each company actually sits.

Two dates now define Indian pharma’s next twelve months. June 8, 2026 - WuXi AppTec designated. The manufacturing story starts now. November 27, 2026 - FDA decision on Zydus’s saroglitazar NDA. The innovation story reaches its first major verdict.

30-minute analysis in this episode.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com

India has 135 approved biosimilars. More than any country on earth. So why has only ONE Indian pharma company built a biologics business that the world has actually heard of?

It’s what happens when a listed pharma company creates a biologics subsidiary, gives it a futuristic name, a modest budget, and a press release and then waits to see whether the world forces it to take it seriously.

We mapped ten such subsidiaries and found:

→ CuraTeQ (Aurobindo) got three EMA approvals in a single calendar year. Indian pharma has never done that before.

→ Enzene (Alkem) built a proprietary manufacturing platform that Fidelity’s biotech VC arm co-funded. A US facility opened in New Jersey in September 2025.

→ Gennova (Emcure) is the only Indian pharma subsidiary with an operational mRNA platform. CEPI funded their Nipah vaccine program.

→ Wockhardt got India’s first biosimilar glargine approval in 2007 five years before EMA. Then financial distress destroyed the program. Hopefully Zaynich can set that right soon.

Most of these subsidiaries function as organisational hedges, not genuine platforms. The subsidiary structure ring-fences capital risk. It also ring-fences leadership attention.

The next five years will sort these ten into three clusters. Two or three will become global platforms. The rest will consolidate, partner, or quietly fade.

Full report in the podcast. Listen in.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com